Kroman Niels, Holtveg Helle, Wohlfahrt Jan, Jensen Maj-Britt, Mouridsen Henning T, Blichert-Toft Mogens, Melbye Mads
Department of Epidemiology Research, Danish Epidemiology Science Center, Statens Serum Institut, Copenhagen, Denmark.
Cancer. 2004 Feb 15;100(4):688-93. doi: 10.1002/cncr.20022.
Among middle-aged and older women with early breast carcinoma, breast-conserving therapy (BCT) has been shown to have an effect on survival that is similar to that of modified radical mastectomy (RM). Nonetheless, it remains to be established whether BCT also is the optimal treatment option for early breast carcinoma in young women, because these women generally have more aggressive disease and a higher frequency of local recurrence compared with older women.
We investigated a cohort of 9285 premenopausal women with primary breast carcinoma who were age < 50 years at diagnosis. These women were identified from a population-based Danish breast carcinoma database containing detailed information on patient and tumor characteristics, predetermined treatment regimens, and survival.
In total, 7165 patients (77.2%) were treated with RM, and 2120 patients (22.8%) were treated with BCT. We calculated the relative risk of death within the first 10 years after diagnosis according to surgical treatment and age, both before and after adjustment for known prognostic factors. No increased risk of death was observed among women who received BCT compared with women who underwent RM, regardless of age at diagnosis (< 35 years, 35-39 years, 40-44 years, or 45-49 years), despite the increased risk of local recurrence among young women. Restricting the analysis to women with small tumors (size < 2 cm) yielded similar results.
Despite having a higher rate of local recurrence, young women with breast carcinoma who receive BCT are similar to young women treated with RM in terms of survival.
在患有早期乳腺癌的中老年女性中,保乳治疗(BCT)已被证明对生存率的影响与改良根治性乳房切除术(RM)相似。尽管如此,BCT是否也是年轻女性早期乳腺癌的最佳治疗选择仍有待确定,因为与老年女性相比,这些女性通常患有更具侵袭性的疾病且局部复发频率更高。
我们调查了9285名绝经前原发性乳腺癌女性队列,她们在诊断时年龄小于50岁。这些女性来自一个基于人群的丹麦乳腺癌数据库,该数据库包含有关患者和肿瘤特征、预定治疗方案及生存情况的详细信息。
总共7165例患者(77.2%)接受了RM治疗,2120例患者(22.8%)接受了BCT治疗。我们根据手术治疗和年龄计算了诊断后前10年内死亡的相对风险,在对已知预后因素进行调整前后均进行了计算。与接受RM治疗的女性相比,接受BCT治疗的女性中未观察到死亡风险增加,无论诊断时的年龄(<35岁、35 - 39岁、40 - 44岁或45 - 49岁)如何,尽管年轻女性中局部复发风险增加。将分析限制在肿瘤较小(尺寸<2 cm)的女性中也得到了类似结果。
尽管局部复发率较高,但接受BCT治疗的年轻乳腺癌女性在生存率方面与接受RM治疗的年轻女性相似。